Administration of intravenous immuno-globulin (IGIV) has therapeutic value for preventing infection in allogeneic bone marrow transplant patients and in those with B-cell chronic lymphocytic leukemia. The use of higher-dose IGIV infusions given at a faster rate may offer greater efficacy with safety. It may also offer reduced loss of time from work or school at reduced cost.
Go to Previous Page
Go to Next Page